BioPharmaStock
HomeAsk About StockNewsIdeasHistoryFDA DesignationsElite Program

ICCM

No price yet

Announcements

Nothing here yet

Daily updates

  • IceCure Presents ProSense Breast Cancer Cryoablation Data at EUSOBI 2026Oct 13, 2026

FDA designations

Nothing here yet

News

  • West Cancer Center received IRB approval to begin IceCure's ChoICE study evaluating cryoablation for breast cancerAug 20, 2026
  • IceCure Medical added Adventist Health as a U.S. clinical site for its post-marketing ChoICE breast cancer cryoablation studyAug 6, 2026
  • IceCure supports NCCN petition to include cryoablation in breast cancer treatment guidelines following ProSense FDA clearanceJul 29, 2026
  • The FDA approved IceCure’s post-marketing ChoICE study evaluating ProSense cryoablation for local treatment of low-risk breast cancerMar 11, 2026
  • IceCure Medical cited an independent PLOS One study supporting the safety and efficacy of ProSense® cryoablation for breast fibroadenomasMar 2, 2026

    Bio Pharma Stock

    Where Science Meets Investing.

    BioPharmaStock is a specialized biopharmaceutical investment intelligence company focused exclusively on publicly traded biotechnology and pharmaceutical companies. Our research team continuously analyzes clinical trials, FDA regulatory events, scientific publications, corporate developments, and market catalysts to deliver timely research and exclusive insights for investors seeking opportunities in one of the world's most knowledge-intensive sectors.

    ALNJAM ALAALI SOFTWARE DESIGN CO. L.L.C, UAE, Abu Dhabi

    BioPharmaStock LogoBioPharmaStock Logo

    Quick Links

    • Home
    • Ask About Stock
    • News
    • Ideas
    • History
    • FDA Designations
    • Elite Program

    Contact Us

    Email: info@biopharmastock.com

    Phone: +971 50 936 3328

    Join Our Community→

    Follow Us

    Get the App

    Instant notifications on your phone

    Download on theApp StoreGet it onGoogle Play

    © 2026 Bio Pharma Stock. All rights reserved. Policy